CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $5,199,000 | -89.0% | 85,549 | -72.2% | 0.02% | -85.5% |
| Q4 2020 | $47,054,000 | +92.0% | 307,320 | +4.9% | 0.12% | +59.0% |
| Q3 2020 | $24,510,000 | +21.3% | 293,041 | +6.6% | 0.08% | +9.9% |
| Q2 2020 | $20,204,000 | +63.5% | 274,917 | -5.6% | 0.07% | +29.1% |
| Q1 2020 | $12,357,000 | -28.2% | 291,374 | +3.2% | 0.06% | -3.5% |
| Q4 2019 | $17,202,000 | +17.5% | 282,434 | -20.9% | 0.06% | +14.0% |
| Q3 2019 | $14,634,000 | +10.2% | 357,021 | +58.0% | 0.05% | +28.2% |
| Q2 2018 | $13,278,000 | +209.6% | 225,970 | +6.7% | 0.04% | +200.0% |
| Q4 2016 | $4,289,000 | – | 211,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |